Overview

Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)

Status:
Unknown status

Trial end date:
2013-12-01

Target enrollment:

Participant gender:

Summary

Men with castrate resistant prostate cancer who are switched from a luteinizing hormone-releasing hormone (LHRH) antagonists from a LHRH agonist will experience a fall in prostate-specific antigen (PSA).

Phase:

Phase 2

Details

Lead Sponsor:

British Columbia Cancer Agency

Collaborator:

Ferring Pharmaceuticals